PTO/SB/08a and 08b (09-08)
Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 6

Complete if known	
Application Number	10/588,166
Filing Date	August 2, 2006
First Named Inventor	Pedro Cuevas Sanchez, et al.
Art Unit	1628
Examiner Name	Anna Pagonakis
Attorney Docket Number	544940-202.1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number / Number-Kind Code[2] (if known)	Publication Date MM-YYYY	Name of Patentee or Applicant of Cited Document	Classification
/A.P./	AA	US-2002/0143052	10-2002	Lan-Hargest, et al.	
	AB	US-2003/0216418	11-2003	Stogniew, et al.	
	AC	US-2004/0167222	08-2004	Brooks, et al.	
	AD	US-2005/0175559	08-2005	Dinardo, et al.	
	AE	US-2006/0258730	11-2006	Allegretti, et al.	
	AF	US-2007/0149618	06-2007	Cuevas Sanchez et al.	
	AG	US-2007/0032471	02-2007	Torrens-Jover et al.	
	AH	US-2008/0114075	02-2008	Cuevas Sanchez et al.	
	AI	US-2008/0125485	05-2008	Cuevas Sanchez, et al.	
	AJ	US-2008/0113947	05-2008	Cuevas Sanchez, et al.	
	AK	US-2008/0113948	05-2008	Cuevas Sanchez, et al.	
	AL	US-2008/0114060	05-2008	Cuevas Sanchez, et al.	
	AM	US-2008/0125486	05-2008	Cuevas Sanchez, et al.	
	AN	US-2008/0114063	05-2008	Cuevas Sanchez, et al.	
	AO	US-2009/0111779	04-2009	Cuevas Sanchez, et al.	
	AP	4,115,648	09-1978	Esteve-Subirana, Antonio	
	AQ	4,837,378	06-1969	Borgman, Robert J.	
	AR	4,970,202	11-1990	Trigger	
	AS	5,519,018	05-1996	Matusch, et al.	
	AT	5,698,595	12-1997	Boelle, et al.	
	AU	6,281,203	08-2001	Touzan, et al.	
	AV	6,664,406	12-2003	Coupland, et al.	
/A.P./	AW	6,787,573	09-2004	Nottet	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document / Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-YYYY	Country	Name of Patentee or Applicant of Cited Document	T[6]
/A.P./	AX	EP 1 719 509 A1	11-2005	EP		
/A.P./	AY	EP 0 204 987 B1	11-1991	EP		
/A.P./	AZ	WO 2005/077352	08-2005	WIPO		
/A.P./	BA	WO 2005/013962	02-2005	WIPO		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a and 08b (09-08)
Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 6

Complete if known	
Application Number	10/588,166
Filing Date	August 2, 2006
First Named Inventor	Pedro Cuevas Sanchez, et al.
Art Unit	1628
Examiner Name	Anna Pagonakis
Attorney Docket Number	544940-202.1

/A.P./	BB	WO 96/17589	06-1996	WIPO		
/A.P./	BC	WO 2006/029484	03-2006	WIPO		
/A.P./	BD	WO 2006/069806	07-2006	WIPO		
/A.P./	BE	WO 96/25159	08-1996	WIPO		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
/A.P./	BF	Actinic Keratosis and Other Precancers. The Skin Cancer Foundation. www.skincancer.org, 2008.	
/A.P./	BG	Arhanic, V., et al., "Attempts at Treating Rubeosis with Angioprotective Agents" Annals of the Dr. M. Stojanovic Hospital (1976) Vol. 15, No. 2 pp. 120-123 (with English translation)	
	BH	Banker et al. Modern Pharmaceutics, 3ed.; Marcel Dekker, New York, 1996, page 596	
	BI	Barrett's disease: http://digestive-system.emedtv.com/barrett's-esophagus/casues-of-Barrett's-esophagus.html, Nov, 2006	
	BJ	Brannon, http://dermatology.about.com/es/eczemadermatitis/a/atopictx.htm. Atopic Dermatitis Treatment.	
	BK	Catalogo de especialidades farmaceuticas 1991, Consejo General de Colegios Oficiales De Farmaceuticos, Madrid, Spain, p. 674 Acnisdin and Acnisdin Retinoico entries (with summary in English)	
	BL	Crohn's disease: http://cholitis.emedtv.com/crohn'sdisease/crohn's-disease-causes.html; (2008)	
	BM	Cuevas et al. Dobesilate in the treatment of plaque psoriasis. Eur. J. Med. Res, 10, 373-376 (2005)	
	BN	Cuevas, P. et al., Treatment of Basal Cell Carcinoma with Dobesilate, Journal of the American Academy of Dermatology, Vol. 53, No. 3 (2005), pp. 526-527	
	BO	Definition of rosacea from American Heritage Medical Dictionary, 2007, www.freedictionary.com	
	BP	Divers et al. Curtis., 2004, vol. 73, no. 4, pages 257-262 (ABSTRACT attached)	
	BQ	Dormond O and Rüegg C, Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives, Drug Resistance Updates (2002) 4, 314-321	
/A.P./	BR	Gambichler T, et al., Cytokine mRNA expression in basal cell carcinoma, Arch Dermatol Res (2006) 298: 139-141	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a and 08b (09-08)
Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 6

Complete if known	
Application Number	10/588,166
Filing Date	August 2, 2006
First Named Inventor	Pedro Cuevas Sanchez, et al.
Art Unit	1628
Examiner Name	Anna Pagonakis
Attorney Docket Number	544940-202.1

/A.P./	BS	Goldman et al. [editors] "Principles of Cancer Therapy." Cecil's Textbook of Medicine (Twenty-First Edition, Volume 1). W.B. Saunders Company. 2000, pages 1060-1074.	
	BT	Graber, R., et al., Calcium Dobesilate protects human peripheral blood mononuclear cells from oxidation and apoptosis, Apoptosis, Vol. 3, No. 1 (1998) pp. 41-49	
	BU	Hodge D, et al., The role of IL-6 and STAT3 in inflammation and cancer, European Journal of Cancer 41 (2005) 2502-2512	
	BV	Hornheide et al. British Journal of Dermatology, 2005, vol. 152, pages 939-947	
	BW	HORNICK, JL, et al. "A New Chemically Modified Chimeric TNT-3 Monoclonal Antibody Directed Against DNA for the Radioimmunotherapy of Solid Tumors" Cancer Biotherapy & Radiopharmaceuticals (1998) Vol. 13, No. 4, pp. 255-268	
	BX	Jee S-H, et al., Interleukin-6 Induced Basic Fibroblast Growth Factor-Dependent Angiogenesis in Basal Cell Carcinoma Cell Line via JAK/STAT3 and PI3-Kinase/Akt Pathways, J Invest Dermatol (2004)123:1169-1175	
	BY	Jee S-H, et al., "Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptitic activity and tumorigenic potency", Oncogene (2001) 20, 198-208	
	BZ	Jee S-H, et al., "The Phosphotidyl Inositol 3-Kinase/Akt Signal Pathway is Invovled in Interleukin-6-mediated Mcl-1 Upregulation and Anti-apoptosis Activity in Basal Cell Carcinoma Cells", J Invest Dermatol (20020 119: 1121-1127	
	CA	Johnson et al. British J. of Cancer, 2001, 84(10): 1424-1431	
	CB	Jordan VC. Nature Reviews: Drug Discovery, 2, 2003, page 205	
	CC	Kaur et al. An open trial of calcium dobesilate in patients with venous ulcers and stasis dermatitis. International Journal of Dermatology. 2003, 42, 147-152	
	CD	Khawli, LA, et al. "Comparison of Recombinant Derivatives of Chimeric TNT-3 Antibody for the Radioimaging of Solid Tumors" Hybridoma and Hybridomics (2003) Vol. 22, No. 1 pp. 1-10	
	CE	Lameynardie, S. et al., Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats, Eur J of Pharm, Vol. 510 (2005) pp. 149-156	
	CF	Lens et al. Br. J. Nurs., 2008, vol. 17, no. 5, pages 300-305 (ABSTRACT attached)	
	CG	Losa, G., et al., Prevention of Oxidation and Apoptosis in Human Peripheral Blood Mononuclear Cells Exposed to Calcium Dobesilate, Int'l J of Angiology, Vol. 8 (1999) pp. 511-515	
/A.P./	CH	Newell B, et al., "Comparison of the microvasculature of basal cell carcinoma and actinic keratosis using intravital microscopy and immunohistochemistry" British Journal of Dermatology 2003: 149; 105-110	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a and 08b (09-08)
Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 6

Complete if known	
Application Number	10/588,166
Filing Date	August 2, 2006
First Named Inventor	Pedro Cuevas Sanchez, et al.
Art Unit	1628
Examiner Name	Anna Pagonakis
Attorney Docket Number	544940-202.1

/A.P./	CI	Nour, A.F., et al., Preliminary Clinical Study with Calcium Dobesilate in Fibrocystic Disease of the Breast, a pilot study, Acta Therapeutica, Vol. 12, No. 3 (1986) pp. 233-241	
	CJ	O'Grady A, et al." COX-2 Expression Correlates with Microvessel Density in Non-Melanoma Skin Cancer from Renal Tranplant Recipients and Immunocompetent Individuals", Hum Pathol (2004) 35: 1549-1555	
	CK	Oh C-K, et al., "Expression of Basic Fibroblast Growth Factor, Vascular Endothelial Growth Factor, and Thrombospondin-1 Related to Microvessel Density in Nonaggressive and Aggressive Basal Cell Carcinomas" Journal of Dermatology (2003) Vol. 30: 306-313	
	CL	Remington's Pharmaceutical Sciences, pags 420-425, 1980	
	CM	Ruiz, E. et al., Calcium Dobesilate Increases Endothelium- Dependent Relaxation in Endothelium-Injured Rabbit Aorta, Pharmacological Research, Vol. 38, No. 5 (1998), pp. 361-366	
	CN	Rutkowski, Suzanne; Asthma Magazine, p9-12, July/August 2001	
	CO	Sausville et al. (Cancer Research, 2006, vol. 66, pages 3351-3354)	
	CP	Schon et al. 2005, N. England J. Med. 352: 1899-912	
	CQ	Sintov et al. Journal of Controlled Release, 2002, vol. 79, pages 113-122	
	CR	Skov et al., "Basal cell carcinoma is associated with high TNF-χ polymorphism at position — 308" Experimental Dermatology, 2003, 12, 772-776	
	CS	Staibano S et al., "The Prognostic Significance of Tumor angiogenesis in Nonaggressive and Aggressive Basal Cell Carcinoma of the Human Skin" Hum Pathol 1996, 27, 695-700	
	CT	Stanton A, et al. "Expansion of Microvascular Best and Increased Solute Flux in Human Basal Cell Carcinoma in Vivo, measured by Fluorescein Video Angiography" Cancer Research (2003) 63: 3969-3979	
	CU	Stanwell, C., et al., The Erbstatin Analogue Methyl 2,5-Dihydroxycinnamate Cross-Links Proteins and is Cytotoxic to Normal and Neoplastic Epithelial Cells by a Mechanism Independent of Tyrosine Kinase Inhibition, American Association for Cancer Research, Baltimore, MD, Vol. 55, No. 21 (1995) pp 4950-4956	
	CV	Stockfleth et al. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. British Journal of Dermatology, 2001; 144: 1050-1053.	
	CW	Takatsuka et al. Various Analogues to Anthranilic Acid and their Anti-Cancer effects. Mie Medical Journal. Vol. XVII, No. 1, 1997.	
/A.P./	CX	Tjiu J-W, et al., "Cyclooxygenase-2 Overexpressionin Human Basal Cell Carcinoma Cell Line Increases Antiapoptisis, Angiogenesis, and Tumorigenesis" Journal of Investigative Dermatology (2006) 126: 1143-1151	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a and 08b (09-08)
Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 6

Complete if known	
Application Number	10/588,166
Filing Date	August 2, 2006
First Named Inventor	Pedro Cuevas Sanchez, et al.
Art Unit	1628
Examiner Name	Anna Pagonakis
Attorney Docket Number	544940-202.1

/A.P./	CY	Tjiu J-W, et al., "Tuor-Associated Macrophase-Induced Invasion and Angiogenesis of Human Basal Cell Carcinoma Cells by cyclooxygenase-2 Induction" Journal of Investigative Dermatology (2009) 129: 1016-1025	
	CZ	Vippagunta et al., Advanced Drug Delivery Reviews, 48, 2001 pp. 3-26	
	DA	Wolff et al. Burger's Medicinal Chemistry and drug discovery, Fifth Edition. Volume 1: Principles and Practices. 1995	
	DB	Yamada, K., et al., Inhibitory Effect of Diacetyl Gentisic Acid on Melanogenesis, Journal of Japanese Cosmetic Science Society, Nihon Koshohin Kagakkai, Tokyo, JP, Vol. 22, No. 3 (1998) pp 169-174	
	DC	Zaragoza D. F. Side reactions in organic synthesis a guide to successful synthesis design, Weinheim: WILEY-VCH, Vertag Gmbh & Co., KGaA, 2005, Preface.	
	DD	International Search Report for WO05077352 mailed June 22, 2005	
	DE	International Search Report for WO2008020040 mailed February 19, 2008	
	DF	International Search Report for WO2008020039 mailed July 15, 2008	
	DG	International Search Report for WO2008020030 mailed November 09, 2007	
	DH	International Search Report for WO2008020028 mailed November 14, 2007	
	DI	International Search Report for WO2008020027 mailed February 22, 2008	
	DJ	International Search Report for WO2008020042 dated December 06, 2007	
	DK	International Search Report for WO2008020034 mailed December 03, 2007	
	DL	International Search Report for WO2008020033 mailed November 30, 2007	
	DM	International Search Report for WO2008020032 mailed November 26, 2007	
	DN	International Search Report for WO2008020031 mailed November 28, 2007	
	DO	International Search Report for WO2008020037 mailed November 30, 2007	
	DP	International Search Report for WO2008020026 mailed November 28, 2007	
	DQ	International Search Report for WO2008020025 mailed November 27, 2007	
	DR	PCT International Search Report mailed on 22 June 2005 in corresponding International Application No. PCT/ES2005/070017	
	DS	Written Opinion of the International Searching Authority mailed on 22 June 2005 in corresponding International Application No. PCT/ES2005/070017	
	DT	PCT International Search Report mailed on 27 November 2007 in corresponding International Application No. PCT/EP2007/058438	
/A.P./	DU	Written Opinion of the International Searching Authority mailed on 27 November 2007 in corresponding International Application No. PCT/EP2007/058438	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a and 08b (09-08)
Approved for use through 10/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 6

Complete if known	
Application Number	10/588,166
Filing Date	August 2, 2006
First Named Inventor	Pedro Cuevas Sanchez, et al.
Art Unit	1628
Examiner Name	Anna Pagonakis
Attorney Docket Number	544940-202.1

/A.P./	DV	Reply to the Written Opinion in corresponding International Application No. PCT/EP2007/058438	
/A.P./	DW	PCT International Search Report mailed on 22 February 2008 in International Application No. PCT/EP2007/058440	
/A.P./	DX	Written Opinion of the International Searching Authority mailed on 22 February 2008 in International Application No. PCT/EP2007/058440	
/A.P./	DY	Reply to the Written Opinion in International Application No. PCT/EP2007/058440	

DI

Examiner Signature	/Anna Pagonakis/	Date Considered	09/20/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.